Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials.

Markus BredemeierLediane Moreira LopesMatheus Augusto EisenreichSheila HickmannGuilherme Kopik BongiornoRui d'AvilaAndré Luis Bittencourt MorschFernando da Silva SteinGuilherme Gomes Dias Campos

Published in: BMC cardiovascular disorders (2018)

Purine-like XOI may reduce the incidence of adverse CV outcomes. However, higher doses of allopurinol (> 300 mg/day) may be associated with loss of CV protection.

Keyphrases

cardiovascular events
coronary artery disease
cardiovascular disease
systematic review
risk factors
uric acid
type diabetes
metabolic syndrome
adverse drug
adipose tissue